Effects of etidronate on the Enpp1-/- mouse model of generalized arterial calcification of infancy

International Journal of Molecular Medicine

Volumn 36, Issue 1, 2015, Pages 159-165

  Huesa, Carmen ^a   Staines, Katherine A ^a   Millán, Jose Luis ^b   MacRae, Vicky E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Ectonucleotide pyrophosphatase phosphodiesterase 1; Etidronate; Generalized arterial calcification of infancy; Mineralization; Vascular calcification

Indexed keywords

COLLAGEN TYPE 1; ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1; ETIDRONIC ACID; P1NP PROTEIN; PHOSPHODIESTERASE; PROTEIN; UNCLASSIFIED DRUG; BONE DENSITY CONSERVATION AGENT; INORGANIC PYROPHOSPHATASE; PEPTIDE FRAGMENT; PROCOLLAGEN; PROCOLLAGEN TYPE I N-TERMINAL PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CALCIFICATION; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BODY WEIGHT; BONE MASS; BONE STRENGTH; CONTROLLED STUDY; DRUG EFFECT; GENERALIZED ARTERIAL CALCIFICATION OF INFANCY; GROWTH; INFANT DISEASE; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PHENOTYPE; POROSITY; PRIORITY JOURNAL; SKELETAL CALCIFICATION; TRABECULAR BONE; TRABECULAR THICKNESS; TREATMENT DURATION; ANIMAL; AORTA; BLOOD; BONE DENSITY; BONE MINERALIZATION; DISEASE MODEL; DRUG EFFECTS; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; PATHOLOGY; VASCULAR CALCIFICATION;

ANIMALS; AORTA; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CALCIFICATION, PHYSIOLOGIC; DISEASE MODELS, ANIMAL; ETIDRONIC ACID; GENETIC PREDISPOSITION TO DISEASE; MALE; MICE; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PHOSPHORIC DIESTER HYDROLASES; PROCOLLAGEN; PYROPHOSPHATASES; VASCULAR CALCIFICATION; X-RAY MICROTOMOGRAPHY;

EID: 84930368875     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2212     Document Type: Article

References (58)

1. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Höhne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, et al: Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 34: 379-381, 2003.
2. Rutsch F, Vaingankar S, Johnson K, Goldfine I, Maddux B, Schauerte P, Kalhoff H, Sano K, Boisvert WA, Superti-Furga A, et al: PC-1 nucleoside triphosphate pyrophosphohydrolase deficiency in idiopathic infantile arterial calcification. Am J Pathol 158: 543-554, 2001.
3. Nitschke Y and Rutsch F: Modulators of networks: Molecular targets of arterial calcification identified in man and mice. Curr Pharm Des 20: 5839-5852, 2014.
4. Mackenzie NC, Huesa C, Rutsch F and MacRae VE: New insights into NPP1 function: Lessons from clinical and animal studies. Bone 51: 961-968, 2012.
5. -/- mice. PLoS One 7: e32177, 2012.
6. Apschner A, Huitema LF, Ponsioen B, Peterson-Maduro J and Schulte-Merker S: Zebrafish enpp1 mutants exhibit pathological mineralization, mimicking features of generalized arterial calcification of infancy (GACI) and pseudoxanthoma elasticum (PXE). Dis Model Mech 7: 811-822, 2014.
7. -/- mice. Bone 69: 139-147, 2014.
8. Li Q, Guo H, Chou DW, Berndt A, Sundberg JP and Uitto J: Mutant Enpp1asj mice as a model for generalized arterial calcification of infancy. Dis Model Mech 6: 1227-1235, 2013.
9. Hakim FT, Cranley R, Brown KS, Eanes ED, Harne L and Oppenheim JJ: Hereditary joint disorder in progressive ankylosis (ank/ank) mice. I. Association of calcium hydroxyapatite deposition with inflammatory arthropathy. Arthritis Rheum 27: 1411-1420, 1984.
10. Terkeltaub R, Rosenbach M, Fong F and Goding J: Causal link between nucleotide pyrophosphohydrolase overactivity and increased intracellular inorganic pyrophosphate generation demonstrated by transfection of cultured fibroblasts and osteoblasts with plasma cell membrane glycoprotein-1. Relevance to calcium pyrophosphate dihydrate deposition disease. Arthritis Rheum 37: 934-941, 1994.
11. Addison WN, Azari F, Sørensen ES, Kaartinen MT and McKee MD: Pyrophosphate inhibits mineralization of osteoblast cultures by binding to mineral, up-regulating osteopontin, and inhibiting alkaline phosphatase activity. J Biol Chem 282: 15872-15883, 2007.
12. Staines KA, MacRae VE and Farquharson C: The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. J Endocrinol 214: 241-255, 2012.
13. Anderson HC: Molecular biology of matrix vesicles. Clin Orthop Relat Res (314): 266-280, 1995.
14. Moss DW, Eaton RH, Smith JK and Whitby LG: Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations. Biochem J 102: 53-57, 1967.
15. Majeska RJ and Wuthier RE: Studies on matrix vesicles isolated from chick epiphyseal cartilage. Association of pyrophosphatase and ATPase activities with alkaline phosphatase. Biochim Biophys Acta 391: 51-60, 1975.
16. Hessle L, Johnson KA, Anderson HC, Narisawa S, Sali A, Goding JW, Terkeltaub R and Millan JL: Tissue-nonspecific alkaline phosphatase and plasma cell membrane glycoprotein-1 are central antagonistic regulators of bone mineralization. Proc Natl Acad Sci USA 99: 9445-9449, 2002.
17. Murshed M, Schinke T, McKee MD and Karsenty G: Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol 165: 625-630, 2004.
18. Macrae VE, Davey MG, McTeir L, Narisawa S, Yadav MC, Millan JL and Farquharson C: Inhibition of PHOSPHO1 activity results in impaired skeletal mineralization during limb development of the chick. Bone 46: 1146-1155, 2010.
19. Roberts S, Narisawa S, Harmey D, Millán JL and Farquharson C: Functional involvement of PHOSPHO1 in matrix vesicle-mediated skeletal mineralization. J Bone Miner Res 22: 617-627, 2007.
20. Roberts SJ, Owen HC and Farquharson C: Identification of a novel splice variant of the haloacid dehalogenase: PHOSPHO1. Biochem Biophys Res Commun 371: 872-876, 2008.
21. Stewart AJ, Roberts SJ, Seawright E, Davey MG, Fleming RH and Farquharson C: The presence of PHOSPHO1 in matrix vesicles and its developmental expression prior to skeletal mineralization. Bone 39: 1000-1007, 2006.
22. Yadav MC, Simão AM, Narisawa S, Huesa C, McKee MD, Farquharson C and Millán JL: Loss of skeletal mineralization by the simultaneous ablation of PHOSPHO1 and alkaline phosphatase function: A unified model of the mechanisms of initiation of skeletal calcification. J Bone Miner Res 26: 286-297, 2011.
23. Narisawa S, Harmey D, Yadav MC, O'Neill WC, Hoylaerts MF and Millán JL: Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res 22: 1700-1710, 2007.
24. Sakamoto M, Hosoda Y, Kojimahara K, Yamazaki T and Yoshimura Y: Arthritis and ankylosis in twy mice with hereditary multiple osteochondral lesions: With special reference to calcium deposition. Pathol Int 44: 420-427, 1994.
25. Okawa A, Goto S and Moriya H: Calcitonin simultaneously regulates both periosteal hyperostosis and trabecular osteopenia in the spinal hyperostotic mouse (twy/twy) in vivo. Calcif Tissue Int 64: 239-247, 1999.
26. Okawa A, Nakamura I, Goto S, Moriya H, Nakamura Y and Ikegawa S: Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 19: 271-273, 1998.
27. Baba H, Furusawa N, Fukuda M, Maezawa Y, Imura S, Kawahara N, Nakahashi K and Tomita K: Potential role of streptozotocin in enhancing ossification of the posterior longitudinal ligament of the cervical spine in the hereditary spinal hyperostotic mouse (twy/twy). Eur J Histochem 41: 191-202, 1997.
28. Furusawa N, Baba H, Imura S and Fukuda M: Characteristics and mechanism of the ossification of posterior longitudinal ligament in the tip-toe walking Yoshimura (twy) mouse. Eur J Histochem 40: 199-210, 1996.
29. Sali A, Favaloro J, Terkeltaub R and Goding J: Germline deletion of the nucleoside triphosphate pyrophosphohydrolase (NTPPPH) plasma cell membrane glycoprotein-1 (PC-1) produces abnormal calcification of periarticular tissues. In: Ecto-ATPases and Related Ectoenzymes. Vanduffel L and Lemmems R (eds). Shaker Publishing BV, Maastricht, The Netherlands, pp267-282, 1999.
30. Harmey D, Hessle L, Narisawa S, Johnson KA, Terkeltaub R and Millán JL: Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: An integrated model of the pathogenesis of mineralization disorders. Am J Pathol 164: 1199-1209, 2004.
31. Anderson HC, Harmey D, Camacho NP, Garimella R, Sipe JB, Tague S, Bi X, Johnson K, Terkeltaub R and Millán JL: Sustained osteomalacia of long bones despite major improvement in other hypophosphatasia-related mineral deficits in tissue nonspecific alkaline phosphatase/nucleotide pyrophosphatase phosphodiesterase1 double-deficient mice. Am J Pathol 166: 1711-1720, 2005.
32. i and osteopontin mediate pathologic calcification associated with defective PC-1 and ANK expression. J Bone Miner Res 18: 994-1004, 2003.
33. Russell RG: Bisphosphonates: From bench to bedside. Ann NY Acad Sci 1068: 367-401, 2006.
34. Orriss IR, Key ML, Colston KW and Arnett TR: Inhibition of osteoblast function in vitro by aminobisphosphonates. J Cell Biochem 106: 109-118, 2009.
35. Idris AI, Rojas J, Greig IR, Van't Hof RJ and Ralston SH: Aminobisphosphonates cause osteoblast apoptosis and inhibit bone nodule formation in vitro. Calcif Tissue Int 82: 191-201, 2008.
36. Iwata K, Li J, Follet H, Phipps RJ and Burr DB: Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 39: 1053-1058, 2006.
37. Tobias JH, Chow JW and Chambers TJ: 3-Amino-1-hydroxypropylidine-1-bisphosphonate (AHPrBP) suppresses not only the induction of new, but also the persistence of existing bone-forming surfaces in rat cancellous bone. Bone 14: 619-623, 1993.
38. Rutsch F, Böyer P, Nitschke Y, Ruf N, Lorenz-Depierieux B, Wittkampf T, Weissen-Plenz G, Fischer RJ, Mughal Z, Gregory JW, et al; GACI Study Group: Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond infancy in generalized arterial calcification of infancy. Circ Cardiovasc Genet 1: 133-140, 2008.
39. Chong CR and Hutchins GM: Idiopathic infantile arterial calcification: The spectrum of clinical presentations. Pediatr Dev Pathol 11: 405-415, 2008.
40. Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH and O'Neill WC: Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int 75: 617-625, 2009.
41. Otero JE, Gottesman GS, McAlister WH, Mumm S, Madson KL, Kiffer-Moreira T, Sheen C, Millán JL, Ericson KL and Whyte MP: Severe skeletal toxicity from protracted etidronate therapy for generalized arterial calcification of infancy. J Bone Miner Res 28: 419-430, 2013.
42. Huesa C, Zhu D, Glover JD, Ferron M, Karsenty G, Milne EM, Millan JL, Ahmed SF, Farquharson C, Morton NM, et al: Deficiency of the bone mineralization inhibitor NPP1 protects mice against obesity and diabetes. Dis Model Mech 7: 1341-1350, 2014.
43. Sugiyama T, Meakin LB, Galea GL, Jackson BF, Lanyon LE, Ebetino FH, Russell RG and Price JS: Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice. Bone 49: 133-139, 2011.
44. Huesa C, Millán JL, van 't Hof RJ and MacRae VE: A new method for the quantification of aortic calcification by three-dimensional micro-computed tomography. Int J Mol Med 32: 1047-1050, 2013.
45. Huesa C, Yadav MC, Finnilä MA, Goodyear SR, Robins SP, Tanner KE, Aspden RM, Millán JL and Farquharson C: PHOSPHO1 is essential for mechanically competent mineralization and the avoidance of spontaneous fractures. Bone 48: 1066-1074, 2011.
46. Hildebrand T and Ruegsegger P: A new method for the model-independent assessment of thickness in three-dimensional images. J Microscopy (Oxford) 185: 67-75, 1997.
47. Li Q and Uitto J: Mineralization/anti-mineralization networks in the skin and vascular connective tissues. Am J Pathol 183: 10-18, 2013.
48. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP and Rosen CJ; PaTH Study Investigators: The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349: 1207-1215, 2003.
49. Fleisch H, Russell RG and Straumann F: Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212: 901-903, 1966.
50. Felix R, Herrmann W and Fleisch H: Stimulation of precipitation of calcium phosphate by matrix vesicles. Biochem J 170: 681-691, 1978.
51. Thiaville A, Smets A, Clercx A and Perlmutter N: Idiopathic infantile arterial calcification: A surviving patient with renal artery stenosis. Pediatr Radiol 24: 506-508, 1994.
52. Van Dyck M, Proesmans W, Van Hollebeke E, Marchal G and Moerman P: Idiopathic infantile arterial calcification with cardiac, renal and central nervous system involvement. Eur J Pediatr 148: 374-377, 1989.
53. Thomas T, Lafage MH and Alexandre C: Atypical osteomalacia after 2 year etidronate intermittent cyclic administration in osteoporosis. J Rheumatol 22: 2183-2185, 1995.
54. Silverman SL, Hurvitz EA, Nelson VS and Chiodo A: Rachitic syndrome after disodium etidronate therapy in an adolescent. Arch Phys Med Rehabil 75: 118-120, 1994.
55. Russell RG, Smith R, Preston C, Walton RJ and Woods CG: Diphosphonates in Paget's disease. Lancet 1: 894-898, 1974.
56. Smith R, Russell RG and Woods CG: Myositis ossificans progressiva. Clinical features of eight patients and their response to treatment. J Bone Joint Surg Br 58: 48-57, 1976.
57. Kim S, Seiryu M, Okada S, Kuroishi T, Takano-Yamamoto T, Sugawara S and Endo Y: Analgesic effects of the non-nitrogen-containing bisphosphonates etidronate and clodronate, independent of anti-resorptive effects on bone. Eur J Pharmacol 699: 14-22, 2013.
58. Li Q, Sundberg JP, Levine MA, Terry SF and Uitto J: The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene. Cell Cycle 14: 1082-1089, 2015.